US Stock MarketDetailed Quotes
OKYO OKYO Pharma
- 1.030
- +0.030+3.00%
Close Oct 3 16:00 ET
34.85MMarket Cap-1807P/E (TTM)
1.040High1.000Low11.24KVolume1.020Open1.000Pre Close11.57KTurnover0.05%Turnover RatioLossP/E (Static)33.84MShares2.20052wk High-5.92P/B24.64MFloat Cap0.80852wk Low--Dividend TTM23.92MShs Float7.000Historical High--Div YieldTTM4.00%Amplitude0.808Historical Low1.029Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
OKYO Pharma Stock Forum
OKYO Pharma Granted U.S. Patent Covering OK-101's Potential for Treating Symptoms of Dry Eye Disease
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated ...
Benzinga· 2 mins ago
OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company dedicated to developing innovative ocular therapies, has recently announced the grant of a significant European patent. This patent, titled “Compositions Comprising Chemerin Analogs and Methods of Use,” covers the company's novel OK-101 chemerin analogs. Th...
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
OKYO Pharma is set to begin a Phase 2 clinical trial of OK-101 for treating neuropathic corneal pain (NCP) in Q3 2024. This is the first instance of an FDA IND clearance for a drug targeting NCP, a significant unmet medical need. OK-101 has shown statistically significant pain relief in previous trials for dry eye disease and preclinical models of NCP. The 12-week, placebo-controlled trial will be led ...
No comment yet